BRAF and lung carcinoma: This case serves as a call for further research into the molecular underpinnings of BRAF-mutant lung carcinomas and highlights the need for clinical trials to explore novel therapeutic agents targeting specific molecular pathways in patients with non-V600E BRAF mutations.